NBIX

#615
Neurocrine Biosciences, Inc. - Common Stock
158.3 0 USD
+1.22%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
158.30
158.30
년간 변동
1.55
162.39
일일 변동
+1.22%
월간 변동
+22.00%
6달 변화
+4.04%
년간 변동율
+9.17%
이전 종가
156.3 9
Open
158.3 0
저가
158.3 0
High
158.3 0
양
309
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 15.92 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry 전문의약품 및 제네릭 의약품 제조업체
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
30.37
주가매출액비율
5.08

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

뉴스